Inflarx NV logo

IFRX - Inflarx NV News Story

$3.66 -0.0  -0.3%

Last Trade - 20/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £113.5m
Enterprise Value £44.2m
Revenue £n/a
Position in Universe 4717th / 6849

InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants

Mon 1st March, 2021 9:01pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210301:nGNXJHFjH&default-theme=true


JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX),
a clinical-stage biopharmaceutical company developing anti-inflammatory
therapeutics by targeting the complement system, announced today that it has
completed its underwritten public offering of 15,000,000 common shares at a
price of $5.00 per share. For each common share purchased, an investor
received a warrant to purchase a common share at an exercise price of $5.80.
The gross proceeds to InflaRx from the offering were approximately $75
million, before deducting the underwriting discount and other offering
expenses and excluding the exercise of any warrants. The Company intends to
use the net proceeds from the offering primarily to fund research and
development expenses for its clinical and preclinical research and development
activities and for working capital and general corporate purposes.

Guggenheim Securities, LLC and Raymond James & Associates, Inc. served as
joint book-running managers for the offering.

A shelf registration statement relating to the securities being sold in this
offering was filed with the U.S. Securities and Exchange Commission (the
“SEC”) and was declared effective by the SEC on July 17, 2020. The
offering was made only by means of a prospectus and a prospectus supplement. A
prospectus supplement and accompanying prospectus related to the offering have
been filed with the SEC and are available at the SEC’s website located at
www.sec.gov. Copies of the prospectus supplement and accompanying prospectus
related to the offering may be obtained by contacting Guggenheim Securities,
LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York,
NY 10017, or by telephone at (212) 518-9544, or by email to
GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or a solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About InflaRx N.V.:

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused
on applying its proprietary anti-C5a technology to discover and develop
first-in-class, potent and specific inhibitors of C5a. Complement C5a is a
powerful inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded in 2007,
and the group has offices and subsidiaries in Jena and Munich, Germany, as
well as Ann Arbor, MI, USA.

Contacts:

InflaRx N.V.

Jordan Zwick – Chief Strategy Officer
Email: IR@inflarx.de
Tel: +1 917-338-6523

MC Services AG

Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements, which are
often indicated by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “believe,” “estimate,” “predict,”
“potential” or “continue” and similar expressions. Forward-looking
statements appear in a number of places throughout this release and may
include statements regarding our intentions, beliefs, projections, outlook,
analyses and current expectations concerning, among other things, our ongoing
and planned preclinical development and clinical trials; the impact of the
COVID-19 pandemic on the Company; the timing and our ability to commence and
conduct clinical trials; potential results from current or potential future
collaborations; our ability to make regulatory filings, obtain positive
guidance from regulators, and obtain and maintain regulatory approvals for our
product candidates; our intellectual property position; our ability to develop
commercial functions; expectations regarding clinical trial data; our results
of operations, cash needs, financial condition, liquidity, prospects, future
transactions, growth and strategies; the industry in which we operate; the
trends that may affect the industry or us and the risks uncertainties and
other factors described under the heading “Risk Factors” in InflaRx’s
periodic filings with the Securities and Exchange Commission. These statements
speak only as of the date of this press release and involve known and unknown
risks, uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. Given these risks, uncertainties and other
factors, you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as
required by law.

(https://www.globenewswire.com/NewsRoom/AttachmentNg/ae450fab-1d9f-4730-9d27-33cf381d6c59)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.